Cardiovascular Business

The cardiovascular business channel offers news and new technologies to aid the business management of the cardiovascular service line.

Diagnostic and Interventional Cardiology Named 2019 Azbee Awards Finalist for Social Media
News | Cardiovascular Business | March 08, 2019 | Jeff Zagoudis, Associate Editor

March 8, 2019 — Diagnostic and Interventional Cardiology (DAIC) was named a finalist in the Social Media Presence...

 FDA Commissioner Scott Gottlieb Announces Resignation
News | Cardiovascular Business | March 05, 2019 | Jeff Zagoudis, Associate Editor

March 5, 2019 — U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., resigned from his...

Dictation by radiologist using Nuance's technology. More powerful, intelligent voice operated systems were demonstrated at HIMSS 2019 as a way to help reduce physician burn out when using EHRs.

Dictation by radiologist using Nuance's technology. More powerful, intelligent voice operated systems were demonstrated at HIMSS 2019 as a way to help reduce physician burn out when using EHRs. 

Feature | HIMSS | March 05, 2019 | Alex Green, Signify Research

Here are some takeaway insights on key technologies highlighted at the ...

Diagnostic and Interventional Cardiology Honored as Jesse H. Neal Awards Finalist

An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation.

News | Cardiovascular Business | February 25, 2019

February 25, 2019 — Diagnostic and Interventional Cardiology has been recognized as a finalist in the...

GE to Postpone Healthcare IPO Following Biopharmaceutical Business Sale
News | Cardiovascular Business | February 25, 2019 | Jeff Zagoudis, Associate Editor

February 25, 2019 — GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE...

Two devices where safety is being called into question based on clinical data that is being questioned. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Blog | Cath Lab | February 20, 2019

Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...

Medical Bills Financially Burden Almost Half of Cardiovascular Disease Patients
News | Cardiovascular Business | February 11, 2019

February 11, 2019 — Over 45 percent of adult atherosclerotic cardiovascular disease (ASCVD) patients suffer...

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019

The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few...

Researchers raised the question whether an economic benefit should be assessed in FDA reviews. A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters.

A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters. Researchers raised the question whether an economic benefit should be assessed in FDA reviews. 

Feature | Cardiovascular Business | January 14, 2019 | Philip Jacobs, DPhil, Ilke Akpinar, M.D., Thanh Nguyen, M.D., Ph.D., Rupinder Sandhu, M.D., and Lars Thording Ph.D.

In an age when everything in medicine is now looked at though a cost vs. benefit analysis and U.S. government...

GE Submits Initial Public Offering Paperwork for Healthcare Division
News | Cardiovascular Business | December 19, 2018

December 19, 2018 — As part of its plans to spin off its healthcare division into a separate company, GE reportedly...

Affordable Care Act Ruled Unconstitutional in Texas Federal Court
News | Cardiovascular Business | December 17, 2018

December 17, 2018 — A judge of the Federal District Court for the Northern District of Texas ruled the Affordable...

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018

December 12, 2018 — A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the...

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent...

Overlay Init